Results from the Navitor study supported recent FDA approval for the transcatheter aortic valve implantation (TAVI) system. The FDA last month approved the system for treating severe, symptomatic aortic stenosis in those at high or greater risk for open-heart surgery.
Data also demonstrated the benefits of the Amplatzer Amulet left atrial appendage (LAA) occluder, according to a news release. It offers immediate and complete closure of the LAA for patients with AFib at risk of stroke.
Abbott presented both studies at the annual Cardiovascular Research Technologies (CRT) meeting in Washington, D.C.
The findings reinforce the importance of continued advancements in minimally invasive technology that offer hope to patients with debilitating heart conditions,” the comp…